July 2018

New Indications

Blinatumomab (rch) (Blincyto) is now indicated for the treatment of minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL) in patients in complete haematological remission.

Brentuximab vedotin (rch) (Adcetris) is now indicated for the treatment of adults with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.

Tiotropium (bromide monohydrate) (Spiriva Respimat) is now indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au